Company intelligence / Profile preview

Lewis Sanders

New York, New York, United States

Ownership: Private
Employees: ~34
Development stage: Other

Overview

Sanders TDI has advanced molecules to clinical stages, including a non-addictive pain medication (SBS-1000) and two therapies for acute myeloid leukemia; a fourth is expected to enter clinic soon[1].

Therapeutic areas: HematologyImmunologyNeurologyInfectious DiseasesOncology
Modalities: Small moleculeAntibodyBiologic
Industry: Academic Hospital/University/Research

Partnerships

Takeda PharmaceuticalsBridge Medicines

Beyond the preview

Go deeper on Lewis Sanders.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lewis Sanders.

Explore the full profile